文献速递白血病淋巴瘤

mTORC1选择性激活翻译延伸促进慢性淋巴细胞白血病疾病进展

mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2023-09-29

该研究通过靶向敲除mTORC1组分Raptor,在慢性淋巴细胞白血病(CLL)模型中揭示mTORC1对白血病起始与维持的关键作用;在已建立疾病的NSG小鼠中诱导Raptor缺陷可降低CLL样疾病负荷并显著延长生存;雷帕霉素比AZD2014更有效减轻侵袭性CLL样疾病负担,并靶向eEF2/eEF2K翻译延伸轴。

要点

  • Raptor敲除揭示mTORC1对CLL模型中白血病起始和维持必不可少。
  • 已建立疾病的NSG小鼠中诱导Raptor缺陷可降低CLL样疾病负荷并显著延长生存。
  • 雷帕霉素比AZD2014更有效减轻侵袭性CLL样疾病负担,提示侵袭性疾病偏向mTORC1敏感性。

核心结论

  • 研究强调翻译延伸作为疾病进展驱动因素的重要性,并确定eEF2活性失活作为阻断CLL进展的新治疗靶点。

研究设计与样本

  • 研究使用CLL模型,通过靶向敲除mTORC1组分Raptor进行机制研究。
  • 在已建立疾病的NSG小鼠中诱导Raptor缺陷,小鼠移植了Mx1-Raptor CLL祖细胞(PKCα-KR转导的HSPCs)。
  • 比较雷帕霉素与AZD2014在侵袭性CLL样疾病模型中的效果。
  • 用mTOR抑制剂处理原代CLL患者细胞。

主要发现

  • Raptor敲除导致造血干/祖细胞(HSPCs)无法定向B细胞谱系,表明mTORC1对白血病起始/维持至关重要。
  • 在已建立疾病的NSG小鼠中诱导Raptor缺陷后,CLL样疾病负荷降低且小鼠生存显著增加。
  • 在侵袭性CLL样疾病模型中,雷帕霉素比AZD2014更有效减轻疾病负担,提示侵袭性疾病偏向mTORC1敏感性。
  • 雷帕霉素而非依鲁替尼有效靶向mTORC1下游的eEF2/eEF2K翻译延伸调节轴,通过诱导eEF2T56磷酸化使eEF2失活。
  • mTOR抑制剂处理原代CLL患者细胞至少部分通过调节eEF2K/eEF2磷酸化和表达阻止增殖,减少蛋白质合成并抑制MCL1、Cyclin A和Cyclin D2表达。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted deletion of Raptor, a component of mechanistic target of rapamycin complex 1 (mTORC1), reveals an essential role for mTORC1 in initiation/maintenance of leukemia in a CLL model, resulting from a failure for haemopoietic stem/progenitor cells (HSPCs) to commit to the B cell lineage. Induction of Raptor-deficiency in NSG mice transplanted with Mx1-Raptor CLL progenitor cells (PKCα-KR-transduced HSPCs) after disease establishment revealed a reduction in CLL-like disease load and a significant increase in survival in the mice. Interestingly in an aggressive CLL-like disease model, rapamycin treatment reduced disease burden more effectively than AZD2014 (dual mTORC1/2 inhibitor), indicating a skew towards mTORC1 sensitivity with more aggressive disease. Rapamycin, but not ibrutinib, efficiently targeted the eEF2/eEF2K translation elongation regulatory axis, downstream of mTORC1, resulting in eEF2 inactivation through induction of eEF2T56 phosphorylation. mTOR inhibitor treatment of primary patient CLL cells halted proliferation, at least in part through modulation of eEF2K/eEF2 phosphorylation and expression, reduced protein synthesis and inhibited expression of MCL1, Cyclin A and Cyclin D2. Our studies highlight the importance of translation elongation as a driver of disease progression and identify inactivation of eEF2 activity as a novel therapeutic target for blocking CLL progression.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Malik N, Hay J, Almuhanna HNB, et al. mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia. 2023. PMID: 37775560. doi:10.1038/s41375-023-02043-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。